MXPA01002475A - Bacterial strains for the production of 2-keto-l-gulonic acid - Google Patents
Bacterial strains for the production of 2-keto-l-gulonic acidInfo
- Publication number
- MXPA01002475A MXPA01002475A MXPA/A/2001/002475A MXPA01002475A MXPA01002475A MX PA01002475 A MXPA01002475 A MX PA01002475A MX PA01002475 A MXPA01002475 A MX PA01002475A MX PA01002475 A MXPA01002475 A MX PA01002475A
- Authority
- MX
- Mexico
- Prior art keywords
- strain
- adm
- nrrl
- culture
- sorbose
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 48
- VBUYCZFBVCCYFD-NUNKFHFFSA-N 2-dehydro-L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-NUNKFHFFSA-N 0.000 title claims abstract description 14
- 230000001580 bacterial Effects 0.000 title abstract description 25
- LKDRXBCSQODPBY-AMVSKUEXSA-N (3S,4R,5S)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims abstract description 36
- 239000002158 endotoxin Substances 0.000 claims abstract description 29
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 230000003000 nontoxic Effects 0.000 claims abstract description 11
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 11
- 239000002609 media Substances 0.000 claims description 58
- 244000005700 microbiome Species 0.000 claims description 58
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000011780 sodium chloride Substances 0.000 claims description 23
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 17
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
- 229960002920 sorbitol Drugs 0.000 claims description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 15
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 14
- 229960000318 kanamycin Drugs 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 13
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims description 12
- 230000001131 transforming Effects 0.000 claims description 12
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 11
- 229960000367 Inositol Drugs 0.000 claims description 11
- 229960005150 glycerol Drugs 0.000 claims description 11
- BJHIKXHVCXFQLS-PYWDMBMJSA-N keto-D-sorbose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PYWDMBMJSA-N 0.000 claims description 10
- 239000001963 growth media Substances 0.000 claims description 9
- 241000589232 Gluconobacter oxydans Species 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 claims description 4
- 229960002180 Tetracycline Drugs 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- 229960000723 ampicillin Drugs 0.000 claims description 4
- 230000003115 biocidal Effects 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000002194 synthesizing Effects 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 3
- 229960005091 Chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 3
- 241001467578 Microbacterium Species 0.000 claims description 3
- 229960005322 Streptomycin Drugs 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 229960000268 spectinomycin Drugs 0.000 claims description 3
- 241000589220 Acetobacter Species 0.000 claims description 2
- 241000186146 Brevibacterium Species 0.000 claims description 2
- 241000588698 Erwinia Species 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000589634 Xanthomonas Species 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 241000589236 Gluconobacter Species 0.000 claims 1
- 108091007521 restriction endonucleases Proteins 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N Pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 abstract description 2
- 210000004027 cells Anatomy 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 238000000034 method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 229960001031 Glucose Drugs 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000007640 basal medium Substances 0.000 description 11
- 235000010633 broth Nutrition 0.000 description 11
- 230000002068 genetic Effects 0.000 description 11
- 229920001817 Agar Polymers 0.000 description 10
- 239000008272 agar Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940041514 Candida albicans extract Drugs 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 230000000813 microbial Effects 0.000 description 7
- -1 rare earth salts Chemical class 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamins Natural products 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 4
- 229940045184 Malt extract Drugs 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 241000927543 Pseudogluconobacter Species 0.000 description 3
- BJHIKXHVCXFQLS-OTWZMJIISA-N Sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 3
- 229940088594 Vitamin Drugs 0.000 description 3
- 241000209149 Zea Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002759 chromosomal Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000005824 corn Nutrition 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000153 supplemental Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- RXMWXENJQAINCC-DMTCNVIQSA-N 2,5-didehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)C(=O)C(O)=O RXMWXENJQAINCC-DMTCNVIQSA-N 0.000 description 2
- IZSRJDGCGRAUAR-MROZADKFSA-N 5-dehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IZSRJDGCGRAUAR-MROZADKFSA-N 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N BAY VP 2674 Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 229960001139 Cefazolin Drugs 0.000 description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 Cefoxitin Drugs 0.000 description 2
- 229960000484 Ceftazidime Drugs 0.000 description 2
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N Ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- RGHNJXZEOKUKBD-SKNVOMKLSA-N L-idonic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SKNVOMKLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940049954 Penicillin Drugs 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JTSDBFGMPLKDCD-XVFHVFLVSA-N TILMICOSIN Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960004659 Ticarcillin Drugs 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229910000147 aluminium phosphate Chemical class 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- 230000001851 biosynthetic Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- 229960005229 ceftiofur Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960000740 enrofloxacin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003760 florfenicol Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000009343 monoculture Methods 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920000023 polynucleotide Polymers 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960000223 tilmicosin Drugs 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N (+)-Ascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- QJVHTELASVOWBE-AGNWQMPPSA-N (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-Benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-Hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DVARTQFDIMZBAA-UHFFFAOYSA-O Ammonium nitrate Chemical compound [NH4+].[O-][N+]([O-])=O DVARTQFDIMZBAA-UHFFFAOYSA-O 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229940098164 Augmentin Drugs 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 244000177578 Bacterium linens Species 0.000 description 1
- 240000000772 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- ATTTYDOGGQCDDK-UHFFFAOYSA-N C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 Chemical compound C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 ATTTYDOGGQCDDK-UHFFFAOYSA-N 0.000 description 1
- 229940105657 CATALASE Drugs 0.000 description 1
- SXVBHNXTPNLOKR-FCLWLKJISA-L Calcium alginate Chemical compound [Ca+2].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O SXVBHNXTPNLOKR-FCLWLKJISA-L 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 229940106195 Cephalothin Drugs 0.000 description 1
- 210000003578 Chromosomes, Bacterial Anatomy 0.000 description 1
- 229920002759 Circular DNA Polymers 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229940093530 Coenzyme A Drugs 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 1
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229940013640 Flavin Mononucleotide Drugs 0.000 description 1
- 229940093632 Flavin-Adenine Dinucleotide Drugs 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 229960002182 IMIPENEM Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229960002064 Kanamycin Sulfate Drugs 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000007443 Lobaria pulmonaria Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229920001776 Mature messenger RNA Polymers 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N Methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 241000983412 Microbacterium saperdae Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N Myoinositol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- IJROUPFSQHMOBK-UHFFFAOYSA-N NC(=N)NN=O.O=NN(C)C(=N)N[N+]([O-])=O Chemical compound NC(=N)NN=O.O=NN(C)C(=N)N[N+]([O-])=O IJROUPFSQHMOBK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 229940053487 Niacinamide Drugs 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 108020005203 Oxidases Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 241000927541 Pseudogluconobacter saccharoketogenes Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N Rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229960002477 Riboflavin Drugs 0.000 description 1
- AUNGANRZJHBGPY-OUCADQQQSA-N Riboflavin Natural products OC[C@@H](O)[C@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-OUCADQQQSA-N 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229940074410 Trehalose Drugs 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000319304 [Brevibacterium] flavum Species 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229920002847 antisense RNA Polymers 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical class [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Chemical class 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical class 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-M cyanoformate Chemical compound [O-]C(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-M 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 102000034327 globular proteins Human genes 0.000 description 1
- 108091005889 globular proteins Proteins 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical class [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N molybdenum Chemical class [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Chemical class 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 229960002862 pyridoxine Drugs 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004215 spores Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000011573 trace mineral Chemical class 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical class [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Chemical class 0.000 description 1
- ZJSAHDQVNRJQGU-UHFFFAOYSA-N urea;nitrate Chemical compound NC(N)=O.[O-][N+]([O-])=O ZJSAHDQVNRJQGU-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Abstract
The present invention relates to novel bacterial strains useful for the production of 2-keto-L-gulonic acid. The present invention further relates to the use of these strains for the production of 2-keto-L-gulonic acid by fermentative conversion of L-sorbose. The present invention further relates to the use of these novel bacterial strains for the production of pyrroloquinoline quinone and a nontoxic lipopolysaccharide. Also described is the strains of the present invention transformed by a vector.
Description
BACTERIAL CEPAS FOR THE PRODUCTION OF 2-CETO-L-GULONIC ACID
BACKGROUND OF THE INVENTION FIELD OF THE INVENTION The present invention relates to novel bacterial strains useful for the production of 2-keto-L-gulonic acid. The present invention also relates to the use of these strains for the production of 2-keto-L-gulonic acid by fermentative conversion of L-sorbose. The present invention also relates to the use of those novel bacterial strains for the production of pyrroloquinoline quinone and a non-toxic lipopolysaccharide. The strains of the present invention transformed by a vector are also described.
BACKGROUND INFORMATION 2-keto-L-gulonic acid ("2-KLG") is a significant intermediate in the preparation of L-ascorbic acid (vitamin C), an essential nutrient. 2-KLG has been synthesized in the past on an industrial scale using the Reichstein method. ' { Helvética Chimi ca Acta 17: 311 (1934)). This method, however, has a number of disadvantages for the commercial application, including the use Ref: 127532 of large quantities of solvents and the involvement of a number of complex reaction steps. Consequently, as an alternative to the Reichstein method, a number of processes have been developed that employ one or more microorganisms to produce 2-KLG by fermentation. U.S. Patent No. 2,421,611, for example, describes a method involving the microbial oxidation of D-glucose 5-keto-D-gluconic acid, followed by chemical or microbial reduction to L-idonic acid and subsequent microbial oxidation to 2-KLG. Japanese Patent Publications Nos. 39-14493, 53-25033, 56-15877 and 59-35290, for example, describe similar processes involving the microbial oxidation of D-glucose to 2,5-diketo-D-gluconic acid. followed by microbial or chemical reduction to 2-KLG. These methods, however, also suffer from a number of disadvantages that reduce their utility in the commercial production of 2-KLG. For example, the steps of chemical reduction in these methods (ie the reduction of 5-keto-D-gluconic acid to L-idonic acid and 2,5-diketo-D-gluconic acid to 2-KLG) are accompanied by problems with control of the stereochemistry of the reduction (thereby producing D-gluconic acid and 2-keto-D-gluconic acid, respectively, as by-products) which, in turn, reduces the yield of 2-KLG. Alternatively, when this reduction is effected by one or more microorganisms, an excess of sugar is required to provide a source of energy for the reduction, which also reduces the yield of 2-KLG. In view of these problems, an alternative route has been used for the fermentative production of 2-KLG, which only involves the oxidation of L-sorbose to 2-KLG via an intermediary of sorbosone. A number of processes using this route have been developed that employ a wide range of microorganisms of the Glucono-acter genera, such as Gluconoba cter oxydans (US Pat.
4,935,359; 4,960,695; 5,312,741; and 5,541,108), Pseudogluconobacter, such as Pseudogl uconobacter saccharoketogenes (U.S. Patent No. 4, 877, 735;
European Patent No. 221 707), Pseudomonas, such as Pseudomonas sorbosoxidans (U.S. Patent Nos. 4,933,289 and 4,892,823), and mixtures of microorganisms of these and other genera, such as Acetobacter, Bacillus, Serra tia, Mycoba cterium, and Streptomyces. (U.S. Patent Nos. 3,912,592; 3,907,639; and 3,234,105). These processes, however, suffer from certain disadvantages that limit their usefulness for the commercial production of 2-KLG. For example, the processes referenced above that employ G. oxydans also require the presence of an additional "aid" microbial strain, such as Bacillus mega terium, or commercially unattractive amounts of yeast or growth components. yeast derivatives to produce sufficiently high levels of 2-KLG for commercial use. In a similar way, processes employing Pseudogluconobacter may require supplemented medium are expensive and unusual rare earth salts or the presence of a support strain, such as B. mega terium, and / or the presence of yeast to achieve commercially adequate 2-KLG concentrations and the efficient use of the sorbose substrate. Other processes employing Pseudomonas sorbosoxidans also include commercially unattractive amounts of yeast or yeast extract in the medium. Pyrroloquinolin quinone (PQQ) (2,7,9-tricarboxy-lH-pyrrolo [2, 3-f] quino-lin-4,5-dione) was initially isolated from cultures of methylotrophic bacteria (using methanol) and more Later it was found to be present in many animal tissues. The structure of the PQQ is as follows:
PQQ can be a novel vitamin since it is essential for normal growth and development. When fed to animals as a supplement, the PQQ prevents oxidative changes that would commonly occur. In addition, PQQ increases the synthesis of nerve growth factor in mouse astrogial cells and has potential for a therapeutic role in the brain. (Bishop, et al., "Pyrroioquinoline Quinone: A Novel Vitamin", Nutri tion Reviews 56: 281-293 (1998) Organic chemical synthesis is the conventional means of producing PQQ, however, organic chemical synthesis has numerous disadvantages For example, chemical synthesis is uneconomical and time-consuming because the synthesis requires multiple and sometimes complicated reaction steps and produces low yields.Therefore, the need to overcome the disadvantages of synthetic chemical techniques for the production of PQQ it has been partially met by the use of bacterial strains for the production of PQQ (US Patents Nos. 4,944,382 and 5,344,768) However, the need still exists for strains of microorganisms that produce more efficient and economical PQQ 5 Lipopolysaccharide (LPS) ) is an amphipathic molecule which is a component of the cell wall of many gram negative bacteria. has been implicated in much of the pathophysiology associated with gram-negative infections in humans and animals. The LPS of Rhodoba character
Sphaeroides is non-toxic and has various uses as an immunomodular and antitumor agent. However, there are several disadvantages associated with the production of non-toxic LPS through Rhodoba cter sphaeroides, for example, the inconvenience of cultivating phototrophically. 5 BRIEF DESCRIPTION OF THE INVENTION The present invention provides strains of microorganisms which efficiently produce 2- keto-L-guiónico acid. Another embodiment of the present invention is directed to strains for the production of 2-keto-L-gulonic acid in cooperation with aid strains. A further embodiment of the present invention provides a method for producing PQQ.
Another embodiment of the present invention is to provide a method for producing a non-toxic LPS. A further embodiment of the present invention is to provide the bacterial strains of the present invention transformed by a vector, and a method for the transformation of the bacterial strains by a vector. These and other embodiments are achieved by the methods of the present invention, which, in a first embodiment, is directed to a culture of any of the strains of microorganisms ADM 291-19 (NRRL B-30035), ADM 62A-12A (NRRL B-30037N), ADM 266-13B (NRRL B-30036), or mutants thereof. Other features and advantages of the present invention will be set forth in the detailed description of the following preferred embodiments, and in part will be apparent from the description or may be learned by practice of the invention. Those advantages of the invention will become reality and will be achieved by the methods particularly indicated in the written description and the claims thereof. It should be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to provide additional explanation of the claimed invention.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a description of the RiboPrint® standards of bacterial strains capable of producing 2-KLG from L-sorbose, the RiboPrint1® standards were obtained from the following bacterial strains: ADM X6L (NRRL B-21627), ADM 291-19 (NRRL B-30035), ADM 266-13B (NRRL B-30036), ADM 62A-12A (NRRL B-30037N), DSM 4025C (a reisolation of the component strain of the colony small from mixed culture tank DSM 4027, US Patent No. 4,935,359), Pseudogl uconoba cter sa ccharoketogenes strain IFO 14484 and Pseudomonas sorbosoxidans strain IFO 14502.
DETAILED DESCRIPTION OF THE INVENTION In a first embodiment, the present invention is directed to a biologically pure culture of a microorganism strain having characteristics that identify it from a strain selected from the group consisting of ADM 291-19
(NRRL B-3035), ADM 64A-12A (NRRL B-30037N), ADM 266-13B (NRRL
B-30036), or mutants thereof. The strains of the microorganism of the present embodiment are capable of producing 2-KLG from L-sorbose by fermentation in pure culture, ie, in the absence of one or more strains of additional microorganisms.
In a further embodiment, the strains of the microorganism of the present invention and strain ADM X6L (NRRL B-21627, US Patent No. 5, -834,231) are capable of producing PQQ from a suitable carbon source. Strains ADM 291-19 and ADM 266-13B were deposited at the Agricultural Research Service Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, USA, on June 18, 1998, under the provisions of the Budapest Treaty and they were assigned access numbers NRRL B-30035 and NRRL B-30036, respectively. The strain ADM 62A-12A-was deposited in the NRRL on August 25, 1998 and assigned the accession number NRRL B-30037N. The characteristics of strains NRRL B-30035, NRRL B-30037N, and NRRL B-30036 include, but are not limited to: (1) Cell morphology - gram negative; it can be variable gram in old crops; thin sticks or coccobacilli; cells that appear alone and in pairs; they can be pleiomorphic; they can form short chains or cells of irregular length; they do not form spores; (2) Colony morphology - punctiform, convex, entire, smooth, butorous and translucent; of khaki or brown coloration in older colonies in some media; (3) Pigment - the colonies produce a diffusible brown pigment, especially on nutrient-rich media containing calcium carbonate and with fructose as the source of carbon. (4) Physiological characteristics: (a) catalase: positive; (b) oxidase: positive (c) gelatinase: negative; (5) Characteristics of the crop: (a) Infusion of Brain and Heart Infusion: growth; (b) growth occurs on liquid DM basal medium (Table 5), without NaCl, or the basal DM medium solidified on agar; (c) does not form films or rings within 24 hours at rest in broth of glucose or mannitol culture at pH in the range of 4.0-5.0; (d) growth in DM liquid basal medium (Table 5), without NaCl, or the basal DM medium solidified in agar, occurs at 4 ° C but not at 37 ° C. The optimum growth temperature is between 25 ° C-30 ° C in DM liquid basal medium (Table 5), without NaCl, or in basal DM medium solidified in agar; (e) the pH optimum for growth in DM basal medium (Table 5), without NaCl, or the basal medium solidified in agar, is between pH 7.0 and pH 8.0;
(6) Antibiotic resistance - sensitive to amikacin, aumentin (amoxicillin -more clavulonic acid), ampicillin, cefazolin, cefoxitin, ceftacidin, ceftiofur, cefalotin, enrofloxacin, florfenicol, gentamicin, imepenem, kanamycin, sarafloxicin, tetracycline, ticarcillin, and tilmicosin , weight resistant to tribissen (aumentin plus sulfamethozole), according to what is determined by the minimum inhibitory concentration (MIC), based on the concentrations of antibiotics "physiologically attainable, using the commercial" Pasco "system, and (7) RiboPrint Analysis ®: The RiboPrint® is an automated ribotyping system that generates and analyzes genetic fingerprints of bacteria.The patterns of genetic fingerprints are standardized digital representations of the genetic data of each sample.The patterns obtained by this method are useful to differentiate not only between organisms of different species, but also in different strains of the same species The RiboPrint® standards for strains NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) and a number of comparative strains that known to be capable of producing 2-KLG from L-sorbose are described in Figure 1. The uniqueness of the bacterial strains can be demonstrated from their RiboPrint® patterns in cases where those patterns are different. In cases where two strains give RiboPrint® patterns that are not distinguishable, the RiboPrint® data are inclusive and other methods are required to show the uniqueness of the strains. One such method is the reassociation of DNA, in which the degree of relationship of the strains is estimated on the entire bacterial chromosome. This can be effected by reciprocal, quantitative cross-hybridization of the chromosomal DNA of the two strains. In the case of strains NRRL B-30035 (ADM 291-19) and NRRL B-30036 (ADM 266-13B), the results of such studies showed a chromosomal similarity of less than 70%, a result that, in the taxonomy Modern bacterial is often associated with strains belonging to separate species (Wayne, LG et al., In t J System, Bacteriol 37: 463-464 (1987)). Thus, the DNA reassortment data unequivocally show that strains NRRL B-30035 (ADM 291-19) and NRRL B-30036 (ADM 266-13B) are unique and different from each other. The ADM X6L bacterial strain (NRRL B-21627) and mutants thereof that produce 2-KLG from L-sorbose via fermentation are described in U.S. Patent No. 08 / 834,231, filed November 10, 1998 and the Application US Serial No. 08 / 893,598, filed July 11, 1997, respectively. The strain and its mutants described in this application are distinct from those of the present invention, as can be seen from a comparison of their RiboPrint standards shown in Figure 1. In addition to the biologically pure strains NRRL-B-30035 ( ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) may also be mutant employees thereof for the production of 2-KLG, provided that these mutants are also capable of producing 2-KLG from L-sorbose. The strains of microorganisms of the present invention, and the mutants thereof, and strains NRRL B-21627 (ADM X6L), and mutants thereof, can also be used for the production of PQQ, provided that the mutants are also capable of producing PQQ. As used herein, a "biologically pure" strain is meant to mean the strain separated from materials with which it is normally associated in nature. Note that a strain associated with other strains, or with compounds or materials not normally found in nature, is still defined as "biologically pure". A monoculture of a particular strain is, of course, "biologically pure". As used herein, a mutant of a given strain of the present invention is derived from one of the strains of the present invention, namely, NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A ) or NRRL B-30036 (ADM 266-13B) or the microorganism strain NRRL B-21627 (ADM X6L). Illustrative examples of suitable methods for preparing the mutants of "strains of microorganisms of the invention include, but are not limited to: mutagenesis by irradiation with ultraviolet light or X-rays, or by treatment with a chemical mutagen such as nitrosoguanidine (N -methyl-N '-nitro-N-nitrosoguanidine), methyl methanesulfonate, nitrogenated mustard and the like; gene integration techniques, such as those mediated by insertion elements or transposons or by homologous recombination of linear or circular DNA transformation molecules; and transduction mediated by bacteriophages. These methods are well known in the art and are described, for example in J.H. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Coid Spring Harbor, New York (1972); J.H. Miller, A Short Course on Genetic Bacterial, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1992); M. Singer and P. Berg, Genes and genomes, University Science Books, Mili Valley, California (1991); J. Sambrook, E.F. Fritsch and T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); P.B. Kaufman et al. , Manual of Molecular and Celular Methods in Biology and Medicine, CRC Press, Boca Raton, Florida (1995); Methods in Biology and Molecular Biotechnology in Plants, B.R. Glick and J.E. Thompson, eds., CRC Press, Boca Raton, Florida (1993); and P.F. Smith-Keary, Molecular Genetics of Escherichia coli, The Guilford Press,. New York, NY (1989). A mutant that produces 2-KLG may or may not have the same biological characteristics of identification of the mother or progeny strain, as long as the mutant produces 2-KLG. A mutant that produces PQQ also may or may not have the same biological characteristics of identification of the parent or progenicora strain, as long as the mutant producesPQQ Mutant strains derived from the organisms of the invention NRRL B-30035 (ADM 2991-19), NRRL B-30037N (ADM 62A-12A), or NRRL B-30036 (ADM 266-13B), or mutants derived from NRRL B -21627 (ADM X6L) using known methods are then preferably selected or separated with their potential for the improved production of 2-KLG and / or PQQ or by other desirable properties related to their utility in the production of 2-KLG from L -sorbose, and / or its utility in the production of PQQ. In accordance with the present invention, a microorganism strain or a mutant thereof of the invention is contacted with L-sorbose for a sufficient time and then the accumulated 2-KLG is isolated. Preferably, the microorganism strain is cultured in a natural or synthetic medium containing L-sorbose for a period of time to produce 2-KLG and accumulated 2-KLG which is subsequently isolated. Alternatively, a preparation derived from cells in the microorganism strain can be contacted with L-sorbose for a sufficient time and the accumulated 2-KLG can then be isolated. In accordance with the present invention, a microorganism strain or a mutant thereof of the invention is cultured in a culture medium comprising a carbon source and a nitrogen source. The source of carbon may be various sugar alcohols, polyols, aldol sugars or keto sugars, including but not limited to arabinose, cellobiose, fructose, glucose, glycerol, inositol, lactose, maltose, mannitol, mannose, rhamnose, raffinose, sorbitol, sorbose, sucrose, trehalose, pyruvate, succinate or methylamine or other substances that can be determined by a person skilled in the art. The medium preferably contains a polyol or aldol sugar, and even more preferably, mannitol, inositol, sorbose, glycerol, sorbitol, lactose and arabinose as the carbon source at a concentration of 0.1% to 20.0% by weight. All the carbon source can be added to the medium before starting the culture, or it can be added step by step or continuously during cultivation.
As used herein, "a preparation derived from cells" is intended to mean any and all cell extracts of the culture broths of a strain or a mutant thereof of the invention, cells dried with acetone, cells immobilized on or within supports, such as polyacrylamide gel, K-carrageenan, calcium alginate and the like, and similar preparations. An illustrative example of such a procedure involves adding L-sorbose and CaC03 in a suitable aqueous buffer, such as 2- (N-methylmorpholino) ethanesulfonic acid (pH 6.5, 0.5 M), to an aqueous extract of the microorganism strain in a flask with agitation. This reaction preferably proceeds at a pH in the range of 6.0 to 8.0 at a temperature in the range of 20 ° C to 40 ° C for about 1 to 100 hours. The concentration of L-sorbose should be from about 0.1 to 10% w / v, more preferably from about 0.3 to 6% (w / v) and the amount of the preparation derived from the cells of the NRRL B strains -30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A) or NRRL B-30036 (ADM 266-13B) or a mutant thereof should be from about 1 to 30 mg / ml. After stirring for a sufficient period of time under empirically determined temperature and pH conditions to maximize the yield of 2-KLG, the accumulated 2-KLG can be isolated by conventional methods.
The medium used herein can be solid or liquid, synthetic (ie, man-made) or natural, and contains sufficient nutrients for the culture of the microorganism strain of the invention. Preferably, the medium used is a liquid medium, more preferably a synthetic liquid medium. The different modalities of the method (which as used herein, is synonymous with processes) of the present invention, the initial material, L-sorbose, may be present in the medium before the introduction of a microorganism know of the invention or it may be added to the medium after the introduction of the strain, either all at once at the beginning or continuously or in parts during the course of the crop, or it can be generated in itself by fermentative conversion of D-sorbitol. The amount of L-sorbose can be determined empirically by one skilled in the art, but is at least sufficient for the strain of the microorganism to produce at least about 40 g / L 2 -KLG. Preferably, the L-sorbose comprises from 3 to 30% (weight / volume) of the culture medium, more preferably from 5 to 20%. In a preferred embodiment of the present invention, the initial L-sorbose material is generated in itself by fermentative conversion of D-sorbitol using a suitable microorganism or mixture of microorganisms.
Any microorganism or mixture of microorganisms that can convert D-sorbitol to L-sorbose in the presence of NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A) or NRRL B-30036 (ADM 266-13B ) or a mutant thereof and which does not adversely affect its ability to convert L-sorbose to 2-KLG can be employed. Preferably, the microorganism used is a strain of Gluconobacter oxydans, most preferably G. oxydans strain ATCC 621 or G. oxydans strain IFO 3293. According to this preferred embodiment of the present invention, the initial material of D- sorbitol may be present in the medium before the production of one or more of the microorganisms or it may be added to the medium after the introduction of one or more of the microorganisms, either all at once at the start or continuously or in parts during the course of cultivation. The natural or synthetic culture medium used in the embodiments of the invention described above and subsequently also contains a source of nitrogen, suitable inorganic salts, and, as appropriate, traces of various nutrients, growth factors and the like suitable for culture. of the microorganism strain, and may also contain at least one supplemental carbon source. The amount of each of those additional ingredients to be employed is preferably selected to maximize the production of 2-KLG and / or PQQ and / or LPS. Such amounts can be determined empirically by one skilled in the art according to the different methods and techniques known in the art. In a particularly preferred embodiment of the present invention, the culture medium used for the production of 2-KLG contains approximately 10%
(weight / volume) of L-sorbose, approximately 3% (weight of dry solids / volume) of macerated corn liquor, and approximately 0.2% (weight / volume) of MgSO4 »7H20 with pH controlled using NH4OH, Ca (OH) 2 or CaC03. In a particularly preferred embodiment of the present invention, the culture medium used for the production of PQQ contains about 5 to 40 g / L of mannitol, glucose, sorbose or inositol, preferably 10 to 20 g / L of mannitol. , glucose, sorbose or inositol and the culture is carried out at a temperature between 0 ° C to 40 ° C, preferably 2 ° C to 35 ° C, and more preferably 20 ° C to 35 ° C. C. The pH of the medium is generally from 6 to 9, preferably from 6.5 to 8.0. The culture time is generally 20 to 150 hours, preferably 20 to 50 hours. In the present embodiment, the PQQ accumulates in the cells and / or culture medium. An illustrative example of the medium for the production of PQQ from ADM X6L (NRRL B-21627) is DM Basal Medium (Table 5), pH 6.0-7.8. In the case of strains ADM 62A-12A, 266-13B, and 291-19, Basal Medium DM without NaCl is used. Instead of mannitol, any other sugar alcohols or polyols such as myo-inositol, sorbose and glucose can be used. The medium to be used in the preparation of the inoculum may contain additional components as appropriate, such as peptone, N-ZAmine, enzymatic soy hydrolyzate, additional yeast extract, malt extract, supplemental carbon sources and various vitamins. Illustrative examples of suitable supplemental carbon sources include, but are not limited to: other carbohydrates, such as glucose, fructose, mannitol, starch or starch hydrolyzate, cellulose hydrolyzate and molasses; organic acids, such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols, such as glycerol, inositol, mannitol and sorbitol. Illustrative examples of suitable nitrogen sources include, but are not limited to: ammonia, including gaseous ammonia and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate; urea; nitrate or nitrite salts, and other nitrogen containing materials, including amino acids such as pure or crude preparations, meat extract, peptone, fish meal, fish hydrolyzate, macerated corn liquor, casein hydrolyzate, soy cake hydrolyzate, yeast extract, dry yeast, ethanol-yeast distillate, soybean meal, cottonseed meal, and the like. Illustrative examples of suitable inorganic salts include, but are not limited to: salts of potassium, calcium, sodium, magnesium, manganese, iron, cobalt, zinc, copper, molybdenum, tungsten and other trace elements, and phosphoric acid. Illustrative examples of traces of appropriate nutrients, growth factors, and the like, include, but are not limited to: coenzyme A, pantothenic acid, pyridoxine-HCl, biotin, thiamine, riboflavin, flavin mononucleotide, flavin adenine dinucleotide, DL- acid 6, 8-thioctic, folic acid, vitamin Bi2, other vitamins, amino acids such as cysteine and hydroxyproline, bases such as adenine, uracil, guanine, thymine and cytosine, sodium thiosulfate, p- or r-aminobenzoic acid, niacinamide, nitriloacetate, and the like, either as pure or partially purified chemical compounds or as they are present in natural materials. The culture of the microorganism strain of the invention can be carried out using any immersion fermentation techniques known to those skilled in the art, such as the low-agitation, traditional air-raised designs, or in agitated culture. The culture conditions employed, including temperature, pH, aeration rate, agitation speed, culture duration, and the like, can be determined empirically by an expert to maximize the production of 2-KLG and / or PQQ. The selection of specific culture conditions depends on factors such as the microorganism strain of the particular invention used, composition and type of medium, culture technique and similar considerations. In a particularly preferred embodiment of the present invention, when using the pure strains NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B) or NRRL B-21627 (ADM X6L) or a mutant thereof, the cultivation takes place at a temperature in the range of 22 ° C to 35 ° C, preferably of about 30 ° C and to a pH in the range of 6.0 to 8.0, preferably in the range of 6.0 to 7.5, more preferably from about 6.5 to 7.5. The culture conditions employed may, of course, be varied by known methods at different points in time during cultivation, as appropriate, to maximize production of 2-KLG and / or PQQ. After cultivation for a sufficient period of time, such as, for example, from 10 to 150 hours, the 2- KLG and / or PQQ that has accumulated in the cells and / or culture broth is isolated according to any of the known methods including ion exchange chromatography, gel filtration, solvent extraction, affinity chromatography, or any combination thereof. Any method that is suitable with the conditions used by the crop can be used; Illustrative examples for suitable methods for recovering 2-KLG are described in U.S. Patent Nos. 5,474,924; 5,312,741; 4,960,695; 4,935,359; 4,877,735; 4,933,289; 4,892,823; 3,043,749; 3,912,592; 3,907,639 and 3,234,105. Illustrative examples of suitable methods for recovering PQQ are described in U.S. Patent Nos. 4,994,382 and 5,344,768. According to one such method for the removal of PQQ, solid-liquid separation, such as filtration and / or centrifugation, is applied to the culture broth to effect the removal of the cells. Either the supernatant, which is the liquid portion that results after the removal of the cells, or the culture broth, which contains the cells, can be used in additional recovery steps. The recovery of PQQ from the supernatant or the culture broth is effected, for example, by ion exchange chromatography, gel filtration, solvent extraction or affinity chromatography.
The identification of the recovered PQQ is made by comparing with pure standard (Fluka Product No. 64682), using, for example, paper chromatography, thin layer chromatography, gel permeation chromatography, elemental analysis, such as mass spectrometry, spectroscopy nuclear magnetic resonance, absorption spectroscopy or high-performance liquid chromatography (CLAP), or a combination thereof. The quantitative analysis of the PQQ can be done using a variant of suppression of the D-glucose dehydrogenase activity of Pseudomonas aeruginosa (Ameyama et al., FEBS Lett 130: 119-183 (1981)) and E. coli (Ameyama et al. al., Agri., Biol. Chem. 49: 1221-1231 (1985)), UV absorption spectrum (Dekker et al., Eur. J. Biochem. 125: 69-73 (1982)), CLAP, gel permeation combined with mass spectrometry or infrared spectroscopy with Fourier transformation (FTIR). According to one such method to recover 2-KLG, at least the microorganisms are removed from the culture broth by known methods, such as centrifugation or filtration, and the resulting solution concentrated in va cuo. The crystalline 2-KLG is then recovered by filtration and, if desired, purified by recrystallization. Similarly, 2-KLG can be recovered using known methods such as the use of ion exchange resins, solvent extraction, precipitation, desalination or the like. When the 2-KLG recovered as a free acid, it can be converted to a salt, as desired, with sodium, potassium, calcium, ammonium or similar cations using conventional methods. Alternatively, when the 2-KLG is recovered as a salt it can be converted to its free form or to a different salt using conventional methods. In an alternative embodiment of the present invention, a microorganism of the invention is cultured in culture mixed with one or more aid strains. As used herein, "aid strain" is intended to mean a strain of a microorganism that increases the amount of 2-KLG and / or PQQ produced in the process of the invention. Suitable aid strains can be determined empirically by one skilled in the art. Illustrative examples of suitable helper strains include, but are not limited to, members of the following genera: Aureoba cterium (preferably L. lichens or A. saperdae), Corybacteriumum (preferably C. ammoniagenes or C. glutamicum), Bacillus, Brevibacterium um (preferably B. linens or B. flavum), Pseudomonas, Proteus, In terobacter, Ci trobacter, Erwinia, Xan thomonas and Flavoba cteri um. Preferably, the help strain is Corynebacterium gumta cum ATCC 21544.
The aid strain is preferably incubated in an appropriate medium under suitable conditions for a sufficient amount of time until a sufficient population culture is obtained. This aid strain inoculum can then be introduced into the culture medium for the production of 2-KLG and / or PQQ either separately or in combination with the microorganism strain of the invention, i.e., a mixed inoculum. Preferably, for the production of 2-KLG, the ratio of the amount of the aid strain to the amount of the strain NRRL-B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A- 12A), 0 NRRL B-30036 (ADM 266-13B) is in the range of 10: 1 to 1: 10,000. Preferably, for the production of PQQ, the ratio of the amount of the aid strain in relation to the amount of strain NRRL B-21627 (ADM X6L) is in the range of 10: 1 to 1:10, 000 Another embodiment of the present invention is directed to the novel microorganism strains described above which are useful in fermentation processes for the production of 2-KLG. A further embodiment of the invention provides a method for isolating a non-toxic lipopolysaccharide (LPS) from NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B) or NRRL B-21627 (ADM X6L) or a mutant thereof. In the context of this embodiment, a mutant is defined as a strain derived from one of the strains of the present invention that produces a non-toxic lipopolysaccharide. The LPS can be purified from the strains of the present invention by any of the methods described in, for example, Strittmater et al. , "Nontoxic Lipopolysaccharide of Rhodopseudomonas sphaeroides ATCC 17023," J. .Bacteriol. 155: 153-158 (1983), Galanos, C. et al. , "A novel method for the extraction of R lipopolysaccharides", Eur. J. Biochem. 9: 245-249 (1969), and Qureshi et al. , "Position of the Ester Group in the Skeleton of Lipid A of Lipopolysaccharides obtained from Salmonella typhimurium" J. Biol. Chem. 258: 12941-12951 (1983). One such method for the production and purification of LPS from NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B) or NRRL B- 21627 (ADM X6L) involves cultivating in a medium comprising 1% Difone's Soytone solution, 1% Difco's Yeast, 0.5% Difco's Malt Extract, 0.5% NaCl, 0.25% K2HP04, 2% mannitol or another suitable carbon source, pH 7.8. Suitable carbon sources can be selected from the group comprising glycerol, mannitol, sorbitol, inositol, glucose and fructose. In the case of ADM guests 62A-12A, 266-13B, and 291-19, media without NaCl are used. Tryptic Soy Broth (Difco) adjusted to pH 7.8 with NaOH could also be used. The cell mass can be grown in liquid media, or in a surface culture on media solidified with 1.3% Bac.to Difco Agar. The wet bacteria are then washed at least once with n-butanol with a content of about 0.1 to 5% acetic acid. The bacteria are then further washed with ethanol, acetone and ether and then dried, for example, in vacuo. The cells are then subjected to extraction with phenol-chloroform-petroleum ether and the obtained LPS are optionally treated again with phenol-chloroform-petroleum ether. The present invention also relates to strains of the present invention transformed with vectors which optionally include at least one marker gene. Recombinant constructs can be introduced into the bacterial strains of the present invention using well known techniques such as transduction, transfection, conjugation, and electroporation or other transformation methods. The vector can be, for example, a phage, plasmid, cosmid or a minichromosome. As defined herein, "host" and "host cells" are synonymous with the cells of the microorganism strains of the present invention. The polynucleotides of interest can be attached to a vector that contains a selectable marker for propagation in the host. A plasmid vector can be introduced into a precipitate, such as a calcium phosphate precipitate, or into a complex with charged lipid. Preferred are vectors comprising control regions of action in the cis position for a polynucleotide of interest. The appropriate trans position acting factors can be supplied by the host, supplied by a complementation vector, or delivered by the vector itself upon introduction into the host. In certain preferred embodiments in this regard, the vectors provide a specific expression, which may be inducible, mutant specific and / or condition specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to handle, such as temperature, nutritional additives or chemical additives. Other suitable environmental factors will be readily apparent to those skilled in the art. Expression vectors useful in the present invention include chromosomal, episomal vectors, for example, vectors derived from plasmids, bacteriophages, and vectors derived from combinations thereof, such as cosmids and phagemids. A DNA insert of interest should be operably linked to an appropriate promoter that is preferably a promoter derived from the host. The expression constructs will also contain sites for the initiation of transcription termination, and in the region described, a ribosomal binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation start codon appropriate for the host at the start and a stop codon appropriately placed at the end of the polypeptide to be translated. According to the indicated, the expression vectors will preferably include at least one marker capable of being selected or separated. Such markers include the genes for resistance to amikacin, augmentin (amoxicillin plus clavulonic acid), ampicillin, cefazolin, cefoxitin, ceftazidime, ceftiofur, cephalothin, chloramphenicol, enrofloxacin, erythromycin, florfenicol, gentamicin, imipenem, kanamycin, penicillin, sarafloxicin, spectinomycin. , streptomycin, tetracycline, ticarcillin, or tilmicosin. Preferred markers include ampicillin, chloramphenicol, erythromycin, kanamycin, penicillin, spectinomycin, streptomycin and / or tetracycline. Other suitable markers will be readily apparent to those skilled in the art. A preferred vector is pMF 1014-a (M. T. Follettie, "DNA Technology for Corynebacterium um gl utamicum: Isolation and Facetization of Biosynthetic Amino Acid Genes", Ph.D. Dissertation
Massachusetts Institute of Technology, Cambridge. Massachusetts (1989)), which comprises the pSRl-a replicon and a determinant of kanamycin resistance. Specifically, pMF 1014-a comprises the pSRl replicon (Archer, JA et al, J. Gen. Mi crobiol 139: 1753-1759 (1993)), and the pSRl-a mutation that allows the reproductive maintenance of the plasmid in hosts of E. coli (Follettie Dissertation, 1989), and the kanamycin resistance gene derived from Tn903 from plasmid pUC4K (Taylor, LA et al, Nuclei c Acids Res. 1 6: 358 (1988)). The present invention provides the strains of the present invention, or mutants thereof, which comprise pMF1014-a. The present invention provides a biologically pure culture of strain of microorganism NRRL B-21627 or a mutant thereof, comprising pMF1014-a. The introduction of the construct into the host cells can be effected by transfection with calcium phosphate, transfection mediated by DEAE-dextran. Transfection mediated by cationic lipid, electroporation and other methods of transformation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al, "Basic Methods in Molecular Biology," (1986). The methods used and described herein are well known in the art and are described more particularly, for example, in J.H. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1972); J.H. Miller, A Brief Course on Bacterial Genetics, Cold Spring Harbor Laboratory Press. Cold Spr: -ng Harbor, New York (1992); M. Singer and P. Berg, Genes and Genomes, University Science Books, Mili Valley, California (1991); J. Sambrook, E.F. Fritsch and T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989); P.B. Kaufman et al, Manual of Molecular and Celular Methods in Biology and Medicine, CRC Press, Boca Raton, Florida (1995); Methods in Biology and Molecular Biotechnology in Plantas, B.R. Glick and J.E. Thompson, eds., CRC Press, Boca Raton, Florida (1993); P.F. Smith-Keary, Molecular Genetics of Escherichia coli, The Guilford Press, New York, NY (1989); Plasmids: An All Practical Me. 2nd Edition, Hardy, K.D., ed., Oxford University Press, New York, NY (1993); Vectors; Da Cough Essentials, Gacesa, P., and Ramji, D.P., eds., John Wiley & Sons Pub. New York, NY (1994); Guide for Electroporation and Electrofusion, Chang, D., et al, eds., Academic Press, San Diego, CA (1992); Promiscuous Plasmids of Gram Negative Bacteria, Thomas, C.M., ed., Academic Press, London (1989); The Biology of Plasmids, Summers, D.K., Blackwell Science, Cambridge, MA (1996); DNA Comprehension and Gene Cloning: A Guide for the Curious, Drica, K., ed., John Wiley and Sons Pub., New York, NY (1997); Vectors: A Molecular Cloning Vector Study and Its Uses, Rodriguez, R.L., et al, eds., Butterworth, Boston, MA (1988); Bacterial Conjugation, Clewell, D.B., ed., Plenum Press, New York, NY (1993); Del Solar, G., al, "Reproduction and control of circular bacterial plasmids", Microbiol. Mol. Biol. Rev. 62: 434-464 (1998); Meijer, W.J., al, "Circular Bacillus subtilis plasmids: complete nucleotide sequences and gene analysis of pTA1015, pTA1040, pTA1050 and pTAlOdO, and comparison with related plasmids of gram positive bacteria", FEMS Microbiol Rev. 21: 37-368
(1998); Khan, S.A., "Cyclic reproduction of bacterial plasmids", Microbiol. Mol. Biol. Rev. 61: 442-455 (1997);
Baker, RL., "Expression of protein using fusion and cleavage of ubiquitin", Curr. Opin. Biotechnol 7: 541-546
(nineteen ninety six); Makrides, S.C., "Strategies for achieving high-level expression of genes in Escherichia coli", Microbiol. Rev.
60: 512-538 (1996): Alonso, J.C., al, "Site-specific recombination in thetata positive gram reproduction plasmids" FEMS Microbiol. Lett. 142: 1-11 (1996); Miroux, B., et al, "Overproduction of protein in Escherichia coli: mutant hosts that allow the synthesis of some membrane protein and globular protein at high levels", J. Mol. Bíol. 260: 289-298 (1996); Kurland, C.G., and Dong, H., "Bacterial growth inhibited by protein overproduction", Mol. Microbiol. 21: 1-4 (1996); Saki, H., and Komano, T., "Reproduction of Plasmid DNA from Wide Host Intervals IncQ in Gram Negative Bacteria" Biosci. Biotechnol. Biochem. 60: 311-382 (1996); Deb, J.K., and Nath, N., "Corynebacteria plasmids," FEMS Microbiol. Lett. 175: 11-20 (1999); Smith, G.P., "Filamentous phages as cloning vectors". Biotechnol 10: 61-83 (1988); Espinosa, M .. el al, "Cyclic reproduction of plasmids and their control" FEMS Microbiol. Lett. 130: 111-120 (1995); Lanka, E., and Wilkins. B.M., "Reaction of DNA processing in bacterial conjugation" Ann. Rev. Biochem. 64: 141-169 (1995); Dreiseikelmann, B., "Translocation of DNA through bacterial membranes" Microbiol. Rev. 58: 293-316 (1994); Nordstrom, K., and Wagner, E.G., "Kinetic aspects of the control of plasmid reproduction by antisense RNA", Trends Biochem. Sci. 19: 294-300 (1994); Frost, L.S., et al, "Analysis of the sequence of genetic products of the sex factor transfer region F", Microbiol. Rev.
5S: 162-210 (1994); Drury, L., "Transformation of bacteria by electroporation," Methods Mol. Biol. 55: 249-256 (1996); Dower, W.J., "Electroporation of bacteria: a general method for genetic transformation", Genet. Eng. 12: 215-295 (1990); Na, S., et al. , "The factors that affect the efficiency of the transformation of coryneform bacteria by electroporation", Chin. J. Biotechnol. 11: 193-198 (1995); Pansegrau, W., "Covalent association of the trand gene product of the RP4 plasmid with the 5'-terminal nucleotide at the site of the relaxation notch" J. Biol. Chem. 265: 10637-10644 (1990); and Bailey J.E., "Host-vector interactions in Escherichia coli", Adv. Biochem. Eng. Biotechnol. 48: 29-52 (1993). The following examples are illustrative and are not intended to limit the scope of the invention as defined by the appended claims. It will be apparent to those skilled in the art that various modifications and variations may be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention as long as they fall within the appended claims and their equivalents.
All patents and publications referred to herein are expressly incorporated by reference.
EXAMPLES
EXAMPLE 1: ISOLATION OF CEPA NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B). A. ORIGIN, ENRICHMENT AND SEPARATION OF SOIL SAMPLES. The environmental specimens were subjected to microbial enrichment in shake flasks. The resulting mixed cultures were separated to identify those that contained at least one strain of microorganism capable of producing 2-KLG from L-sorbose. Samples of wet soil, sand, sediment, fruit, berries, humus and other environmental specimens were collected from the
U.S. Each specimen was immediately stored in a cold, ventilated, moist container. The enrichments were started by adding one gram of soil or specimen to 30 mL of Medium A (Table 1) in a shake flask, with baffles, of 250 mL, followed by incubation with shaking at 30 ° C, 230 rpm, for approximately 2 hours. days . To select or separate enrichments by fermentation, 0.5 to 0.75 mL of each enrichment was transferred to a 250 mL baffled flask containing 30 mL of fresh Medium B (Table 1). These flasks were shaken at 30 ° C, 230 rpm for approximately 3 days, after which portions of the fermentations of the mixed culture were analyzed to determine the content of 2-KLG, and were cryogenically preserved. For preservation, 2.0 mL of each culture was mixed with 1.0 mL of 40% glycerol in sterile water, then stored at -70 ° C. The flasks were selected or separated for the production of 2-KLG using thin layer chromatography on 150 plates of Silica Gel Whatman LK5, 250 mm thick (Catalog No. 4855-820). The plates were stained with 5 μL of centrifuged culture broth, and developed for 5-6 hours in solvent (157 mL of n-propanol, 39 mL of deionized water, 4 mL of 1% phosphoric acid, 0.4 mL of acetic acid). glacial). The plates were air dried and then sprayed with 0.125 g of tetrazolium blue chloride dissolved in 25 mL of methanol and 25 mL of 6N sodium hydroxide, after which they were baked at 60 ° C for 5 minutes. Sorbose and 2-KLG were visualized as purple spots on the finished plates, and were identified by comparison with a standard containing 10 g / L each of 2-KLG and L-sorbose.
The production of 2-KLG was quantified by CLAP.
The samples were prepared by 1:10 dilution in mobile phase, followed by filtration through 0.45 μm porous membranes. The mobile phase contained 1.1 mL of ACS-grade sulfuric acid diluted to 4.0 L using Milli-Q water. Samples of 100 μm each were loaded into two columns of A inex inexhaustive HPX-87H
2 mm x 300 mm x 7.8 mm (BioRad) arranged in series to provide a total column length of 600 mm, preceded by a protective column of the same resin. The column was run at 55 ° C using a flow rate of 0.6 mL / min. L-sorbose and 2-KLG were detected using a Water Model No. 410 differential refractometer, and were identified by comparing with a standard containing 2-KLG and L-sorbose. Thirty-three (33) of the mixed culture fermentations produced 2-KLG, in amounts ranging from 1.8 to 9.3 g / L. Mixed culture fermentations of which strains NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) were subsequently isolated (Example IB) produced 6.9 g / L, 9.3 g / L, and 5.4 g / L of 2-KLG, respectively.
B. ISOLATION AND TEST OF MONOCULTIVES Pure cultures of microorganisms capable of producing 2-KLG were isolated from L-sorbose, either in monoculture or in culture mixed with other microorganisms, of the enrichments described above. Eleven enrichments of mixed culture were chosen in Example IA on the basis of their superior 2-KLG production. These were thawed and diluted at 10-fold serial increments using Medium A, after which 0.1 mL of each dilution was dispersed on the surface of an agar plate of Medium A. The plates were incubated at 30 ° C for 24 hours. hours, then examined under an amplification of 8 to 40 times. Attention was needed to the smaller colonies, which grew more slowly, to recover the 2-KLG-producing strains from the dilution plates. Several examples of each type and size of colony were selected and subcultured on fresh Medium A plates, after which the dilution plates were returned at 30 ° C for 24 hours. Additional slow-growing colonies were selected from the dilution plates and subcultured after a second incubation period. Each strain was purified thoroughly for 1-3 cycles on any of the Medium A plates or in PYM plates (10 g / L of peptone, 10 g / L of yeast extract, 0.5 g / L of glycerol, 30 g / L). L of mannitol, 20 g / L of agar). The pure strains were cryogenically preserved at -70 ° C in PYM liquid medium containing 20% glycerol. A total of 118 pure strains of the eleven enrichment mixtures were recovered. The 118 new strains were tested for their potential to convert L-sorbose to 2-KLG in shake flasks. To take into account the possibility that the production of 2-KLG may require the combined activity of two or more microorganisms, each new isolate was tested in combination in pairs with all the strains that originated from the same enrichment, as well as the pure culture . To prepare the inoculum, each strain was grown on PYM agar for 24 hours, after which a large ring of cells was suspended in sterile buffer containing 50 mM sodium phosphate, 0.4% sodium chloride, and 0.05% mannitol , pH 7.2. For each pure strain or paired strain test, a flask with baffles, 250 mL containing 30 mL of Medium C (Table 1) was inoculated with 0.2 mL of cell suspension from each of the relevant strains. These flasks were shaken at 30 ° C, 230 rpm for 24 hours, after which 1.0 mL was transferred to 30 mL of fermentation medium D (Table 1). The fermentation flasks were shaken at 30 ° C, 230 rpm for three days, then the broth was analyzed to determine the content of 2-KLG and the sorbose content using TLC and CLAP. The flasks containing the strains NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) showed a total pattern of higher levels of 2-KLG. than the flasks that did not contain those strains. These strains were individualized for subsequent studies, as candidates producing 2-KLG.
Table 1: Means used in Example 1
The glucose, macerated corn, iron sulfate and calcium carbonate were adjusted to pH 7.9, then autoclaved for 20 minutes, the remaining ingredients were adjusted to pH 6.3, then sterilized by filtration. The finished medium had a pH in the range of 7.1-7.4. The Yeast Nitrogen Base was the product Difco # 0335-15-9.
EXAMPLE 2: PRODUCTION OF 2-KLG FROM L-SORBOSE BY
STRAINS NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) IN MATRACES WITH AGITATION. For each producing strain, a fresh culture ring grown on agar medium was inoculated in a 250 mL baffled flask, containing 20 mL of
Medium A or B seeded (Table 2), which was stirred at 30 ° C for
22-24 hours at 240 rpm. Two mL of the sowing content was used to inoculate 25 mL of fermentation medium C or D
(Table 2) in a shake flask, with baffles, of 250 mL, and the flasks were shaken for 72-92 hours at 30 ° C, 240 rpm. The broth was later removed and analyzed by CLAR. The results of the production of 2-KLG are shown in Table 3.
Table 2: Means used in Examples 2 and 3
Table 2: Means used in Examples 2 and 3 (continued) Table 2: Means used in Examples 2 and 3 (continued)
Soluble soy was a liquid residual fraction of soybean processing. The amount was expressed as grams of dry solids per liter of medium. ,
Table 3: Production of 2-KLG from L-sorbose by pure cultures in shake flasks
Table 3: Production of 2-KLG from L-sorbose by pure cultures in shake flasks (continued)
* Yield was expressed as grams of 2-KLG produced per 100 grams of initial L-sorbose in the reaction.
EXAMPLE 3: PRODUCTION OF 2-KLG FROM L-SORBOSE BY
MIXED CROPS COMPRISED OF PRODUCER STRAINS NRRL B-30035 (ADM 291-19), OR NRRL B-30037N (ADM 62A-12A), OR NRRL B-30036 (ADM 266-13B), IN COCULTATION WITH A SECOND ORGANISM. For each producing strain, a fresh culture ring grown on agar medium was inoculated into a 250 mL baffled flask containing 20 mL of Medium A (Table 2), followed immediately by inoculation with 100 μL. of a frozen culture of Aureobacterium um liquefaciens strain X6S. The flasks were shaken at 240 rpm for 22-24 hours at 30 ° C. Two mL of this culture was transferred to a 250 L baffled flask containing 25 mL of Medium C, which was then stirred for 72-92 hours at 30 ° C, 240 rpm. The broth was later removed and analyzed by CLAR. The results of the production of 2-KLG are shown in Table 4.
Table 4: Production of 2-KLG from L-sorbose by cultures mixed in flasks
* Yield was expressed as grams of 2-KLG produced per 100 grams of initial L-sorbose in the reaction
EXAMPLE 4: PRODUCTION OF PQQ BY STRAINS NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B), and NRRL B-21627 (ADM X6L) ) IN MATRACES WITH AGITATION. Strain NRRL B-30035 (ADM 291-19), NRRL B-30037N
(ADM 62A-12A), NRRL B-30036 (ADM 266-13B), or NRRL B-21627
(ADM X6L), inoculated in 10 ml of DM Basal Medium (Table 5), pH 7.8 and stirred at 300 rpm, and 30 ° C, until a maximum optical density was reached at a wavelength of 600 nm. In the case of ADM 62A-12A, 266-13B, and 291-19 means were used without NaCl. 5 ml of this culture were transferred to 500 ml of fresh medium in a 2 L baffled flask, which was inoculated with shaking at 300 rpm, 30 ° C, for a sufficient time to reach a maximum optical density at one length 600 nm. To determine the amount of PQQ in the medium, a sample was removed at a predetermined time and centrifuged to obtain a supernatant. The supernatant was analyzed according to the methods of U.S. Patent Nos. 4,994,382 and / or 5,344,768 or by gel permeation chromatography coupled with mass spectrometry.
EXAMPLE 5: EXTRACTION OF A NON-TOXIC LIPOPOLISACARIDE FROM NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B) and NRRL B-21617 (NRRL B-21617) ADM X6L) NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B) or NRRL B-21617 (ADM X6L) was grown in medium which comprised 1% Difone Soytone, 1% Difco Yeast Extract, 0.5% Difco Malt Extract, 0.5% NaCl, 0.25% K2HP04, 2% Mannitol, 2% Jpyo-Inositol, or 2% glucose, or another suitable carbon source, pH 7.8 and stirred at 300 rpm, 30 ° C. In the case of NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), NRRL B-30036 (ADM 266-13B), media out NaCl were used. The cells were then harvested and then washed three times water. 120 g of wet bacteria were then washed three times, each time 600 ml of n-butanol containing about 1% acetic acid. The bacteria were further washed ethanol, acetone and ether (each, three times 600 ml) and dried in vacuo. The dried bacteria were placed in a centrifugation vessel and an extraction mixture (200 ml) was added. The extraction mixture contains liquid phenol (90 g of dry phenol + 11 ml of water), chloroform and petroleum ether
(e.g., 40-60 ° C) in a volume ratio of 2: 5: 8, respectively. This mixture is monophasic when the phenol used is dry. If water is present in the original phenol preparation, the mixture is cloudy and can be rinsed by adding solid phenol. The suspension is then homogenized for 2 minutes cooling, so that the temperature remains between 5 ° and 20 ° C. It does not mean that this treatment breaks the bacteria, but that it is to obtain them in a fine suspension. If the bacteria are already finely suspended, stirring the mixture for a few minutes is sufficient. Sometimes the suspension is very viscous after homogenization. In this case, more extraction mixture is added. The bacteria are then centrifuged (5000 rev / min, 15 min) and the supernatant containing the lipopolysaccharide is filtered through filter paper in a spherical flask. The bacterial residue is extracted once more the same amount of extraction mixture, stirred and centrifuged as above and the supernatant is added to the first extract. The extraction could be repeated a third time. The combined supernatants have a slightly yellow to dark brown color. The petroleum ether and the chloroform are then completely removed on a rotary evaporator at 30-40 ° C (or at high vacuum to less than 0 ° C). If the remaining phenol crystallizes now, enough water is added to dissolve it. The solution is transferred into a cold centrifuge container and water is added dropwise until the lipopolysaccharide precipitates. The addition of water stops when the lipopolysaccharide begins to settle after the mixture is allowed to stand for 1 to 2 minutes. Although the precipitation of lipopolysaccharide is complete long before the phenol is saturated water, care must be taken not to add too much water as this causes the formation of two phases. The precipitated lipopolysaccharide is then centrifuged (3000 rev / min, 10 min), the supernatant is decanted, and the tube is allowed to stand for 2 to 3 minutes flipped down. It is then cleaned internally filter paper. The precipitate is washed two to three times small portions of 80% phenol (approximately 5 ml) and the inside of the tube is cleaned filter paper before decanting the supernatant. Finally, the precipitate is washed three times ether to remove any remaining phenol, and dried in vacuo. The lipopolysaccharide is removed in distilled water (50 ml), heated to 45 ° C, and vacuum is carefully applied to remove the air. It is then stirred for a few minutes, which results in a viscous solution, sometimes very viscous. Viscosity can be reduced by placing the solution in an ultravibrator for 5 minutes. The lipopolysaccharide solution is centrifuged once at high speed (100,000 x g, 4 h). The resulting sediment is clear and transparent, so that sometimes it is difficult to recognize until the supernatant is decanted. The lipopolysaccharide is redissolved in water and lyophilized.
Table 5: Defined Basal Medium (DM) for the characterization of the isolate
Table 5: Defined Basal Medium (DM) for the characterization
of the isolate (CONTINUED) Table 5: Defined Basal Medium (DM) for the characterization of the isolate (Continued) EXAMPLE 6: TRANSFORMATION OF THE STRAIN WITH A VECTOR The bacterial host strain ADM X6L was transformed by electroporation with the plasmid vector pMF1014-a, which comprises the pSRl-a replicon and a kanamycin resistance determinant. The plasmid pMF1014-a was then re-isolated from the resulting ADM X6L transformant and subsequently used to transform an E. coli host. The example demonstrates the transformation of the ADM strains with a vector, the selection of transformants by expression of kanamycin resistance in the ADM host, maintenance of the plasmid as an extrachromosomal element in the ADM host, and the use of pMF1014-a as a launch vector of the new E. Co i / ADM strain. In the ADM of plasmid pMF1014- (MT Follettie, "DNA technology for Corynebacterium glutamicum: isolation and characterization of amino acid biosynthetic genes", Ph.D. Dissertation, MIT, USA, 1989) DNA was isolated using the materials and procedures provided in the "Wizard Plus Midipreps" DNA Purification System (Promega), of a 50 ml overnight culture of E. coli DH5aMCR / pMFl014-a grown in Luria broth (1% Tripcox Difco, 0.5% Difco Yeast Extract, 0.5% NaCl) with 50 μg / ml kanamycin sulfate.
To prepare competent ADM X6L host cells, a single ADM X6L colony was inoculated in 10 ml of X6L Medium (1% Difco Soytone, 1% Difco Yeast Extract, 0.5% Difco Malt Extract, 0.5% of NaCl, 0.25% of K2HP04, 2% of mannitol, pH 7.8) and stirred at 300 rpm, 30 ° C, until 0.8 absorption units were reached at a D? 6oo-In the case of ADM guests 62A- 12A, 266-13B, and 291-19, X6L Medium without NaCl was used. Five ml of this culture was transferred to 500 ml of fresh X6L medium in a 2 L baffled flask, which was incubated with shaking at 300 rpm, 30 ° C, for a sufficient time to reach 1.0 absorption units at a time. DOÉOO • The mature crop was cooled rapidly, and a temperature of 2-4 ° C was maintained during the subsequent steps. The cells were harvested by centrifugation and washed at the resuspension sites with 500 ml of ice-cooled water followed by recentrifugation. The sediment from the second wash was suspended in 40 ml of 10% glycerol cooled on ice, mixed, and recentrifuged. The volume of this sediment was estimated, and the sediment was suspended in an equivalent volume of 10% glycerol cooled with ice. The suspension of competent cells with the resulting transformation was divided into aliquots in microcentrifuge tubes, 40 μL per tube, and stored at -80 ° C.
Two μL of a cold solution containing 140 μg / ml of purified pMF104-a DNA in water was added to 40 μL of cold competent ADM X6L cells, and mixed. The cell-DNA mixture was transferred to a pre-cooled electroporation cuvette (1 mm cuvette, Catalog No. 940-00-100-5, Eppendorf Scientific, Inc.), quickly transferred to an electroporation device "BioRad Gene Pulser II "and was boosted at 1.5 kV, 25 μF, 200 ohms. Immediately after the pulse, 1 ml of X6L medium was added at room temperature to the boosted cells, and the mixture was transferred to a sterile 10 ml test tube and incubated with shaking at 300 rpm, 30 ° C. After two hours of incubation to allow expression of kanamycin resistance, 1.04 ml of cell suspension was removed and microcentrifuged for 2 minutes at 14,000 rpm. 0.9 ml of supernatant was removed, the cell pellet was suspended in the remaining supernatant, and the cell suspension was dispersed on a petri dish of Medium X6L containing 20 μg / ml kanamycin and 1.3% Bacto Agar from Difco. The plate was incubated for 2 days at 30 ° C. Twenty ADM X6L transformant colonies resistant to kanamycin were obtained by this procedure. The X6L transformants maintained the plasmid pMF1014-a as an extrachromosomal element. To demonstrate this, the plasmid DNA was isolated from the X6L transformants using the procedure set forth above for E. coli, except that the transformed X6L cells were grown in X6L Medium containing 40 μg / ml kanamycin. The plasmid DNA isolated from the X6L transformants had the same size as the original pMF1014-a plasmid, as demonstrated by agarose gel electrophoresis. The plasmid isolated from the X6L transformant still had the kanamycin resistance gene and E. coli reproduction determinants. To demonstrate this, competent E. coli cells were prepared by the method of Letterberg and Cohen (J. Bact. 119: 1072-1074, 1964), and transformed with plasmid DNA from the X6L transformants using the D.A. Morrison (J. Bact. 132: 349-351, 1977). The E. coli cells transformed by this method acquired resistance to kanamycin, and showed the presence of a plasmid having the same size as the original plasmid pMF1014-a. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (2)
- CLAIMS Having described the invention as above, the content of the following claims is claimed as property. A biologically pure culture of a microorganism strain, characterized in that it comprises identification characteristics of the strain selected from the group consisting of NRRL B-30035 (ADM 291-19), NRRL B-30037N (ADM 62A-12A), and NRRL B-30036 (ADM 266-13B) or a mutant thereof derived from the strain. 2. The biologically pure culture according to claim 1, characterized in that it comprises the microorganism strain NRRL B-30035 (ADM 291-19) or a mutant thereof derived from the strain. 3. The biologically pure culture according to claim 1, characterized in that it comprises the microorganism strain NRRL B-30037N (ADM 62A-12A) or a mutant thereof derived from the strain. 4. The biologically pure culture according to claim 1, characterized in that it comprises the microorganism strain NRRL B-30036 (ADM 266-13B) or a mutant thereof derived from the strain. 5. A method for the production of 2-keto-L-gulonic acid, characterized in that it comprises cultivating the strain according to claim 1 in a medium comprising L-sorbose for a sufficient time for the L-sorbose to be converted to 2-keto-L-gulonic acid; and recover 2-keto-L-gulonic acid. 6. The method according to claim 5, characterized in that it also comprises converting the acid
- 2-keto-L-gulónico to ascorbic acid or a salt thereof. The method according to claim 6, characterized in that the strain is capable of producing at least about 40 g / L of 2-keto-L-gulonic acid to ascorbic acid or to a salt thereof. The method according to claim 5, characterized in that the cultivation is carried out at a pH of about 6.0 to 8.0 9. The method according to claim 5, characterized in that the cultivation is carried out at a temperature of approximately 22 ° C. up to about 35 ° C. The method according to claim 5, characterized in that the microorganism is cultivated in pure culture. The method according to claim 5, characterized in that the microorganism strain is cultured in a mixed culture comprising at least one additional microorganism strain. 12. The method according to claim 11, characterized in that the additional microorganism strain is a member of a genus selected from the group consisting of Aureoba cterium, Corybacterium, Ba cillus, Brevibacterium, Pseudomonas, Proteus, In terobacter, Ci troba cter, Erwinia, Xan thomonas and Flavobacteri um. The method according to claim 5, characterized in that the L-sorbose is generated by fermentative conversion of D-sorbitol. 14. The method according to the claim 13, characterized in that L-sorbose is generated by the fermentative conversion of D-sorbitol using Gluconobacter oxydans. 15. The method according to claim 14, characterized in that the Gl uconobacter oxydans of the strain ATCC 621 or IFO strain 3293 or a mutant thereof. 16. A method for the production of 2-keto-L-gulonic acid, characterized in that it comprises culturing the strain according to claim 1 in culture mixed with a microorganism strain capable of converting D-sorbitol to L-sorbose in a medium containing D-sorbitol, for a sufficient time for the D-sorbitol to be converted to 2-keto-L-gulonic acid; and recover 2-keto-L-gulonic acid. 17. The method according to claim 16, characterized in that the additional microorganism strain is a member of the genus Gluconobacter or Acetobacter. 18. The method according to claim 17, characterized in that the additional microorganism strain is either Gluconobacter oxydans ATCC 621 or Gluconoba cter oxydans IFO 3293 or mutants thereof. 19. A method for isolating PQQ, characterized in that it comprises: cultivating the strain according to claim 1 in culture medium comprising glucose, sorbose, glycerol, mannitol, sorbitol or inositol; and recover the PQQ. 20. A method for isolating PQQ, characterized in that it comprises: culturing the microorganism strain NRRL B-21627 or a mutant thereof in culture medium comprising glucose, sorbose, glycerol, mannitol, sorbitol or inositol; and recover the PQQ. 21. The method according to the claim 19 or claim 20, characterized in that the microorganism strain or mutant thereof is cultured in a mixed culture comprising at least one additional strain. 22. A method for isolating a non-toxic lipopolysaccharide, characterized in that it comprises culturing the strain according to claim 1 in a medium comprising glycerol, glucose, fructose, mannitol, sorbitol or inositol and recovering the lipopolysaccharide. 23. A method for isolating a non-toxic lipopolysaccharide, characterized in that it comprises culturing the microorganism strain KRRL B-21627 in medium comprising glycerol, glucose, fructose, mannitol, sorbitol or inositol and recovering the lipopolysaccharide. 24. The culture according to claim 1, characterized in that the strain comprises a vector. 25. The culture according to claim 24, characterized in that the vector is pMF 1014-a. 26. A biologically pure culture of microorganism strain MRRL-B-21627 or a mutant thereof, characterized in that it comprises pMF 1014-a. 27. The culture according to claim 24, characterized in that the vector comprises a marker gene. 28. Cultivation in accordance with the claim 27, characterized in that the marker gene comprises a nucleotide sequence that operates to direct the synthesis of a protein that confers resistance to an antibiotic in a host cell. 29. Cultivation in accordance with the claim 28, characterized in that resistance to an antibiotic comprises resistance to ampicillin, chloramphenicol, erythromycin, kanamycin, spectinomycin, streptomycin and tetracycline. 30. The culture according to claim 24, characterized in that the vector comprises (a) an exogenous terminator of transcription; (b) an exogenous promoter; and (c) a discrete series of restriction endonuclease recognition sites, the series is between the promoter and the terminator. 31. A method for transforming the strain according to claim 1, characterized in that it comprises inserting a vector into the strain.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/099,860 | 1998-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01002475A true MXPA01002475A (en) | 2002-02-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2269771C (en) | Novel bacterial strains and use thereof in fermentation processes for 2-keto-l-gulonic acid production | |
Survase et al. | Biotechnological production of vitamins. | |
KR950009199B1 (en) | A method for producing 2-keto-l-gulonis acid | |
US6316231B1 (en) | Bacterial strains for the production of 2-keto-L-gulonic acid | |
JPH05317062A (en) | Method of fermentation | |
US6387654B1 (en) | Bacterial strains and fermentation processes for the production of 2-keto-l-gulonic acid | |
AU2000246957C1 (en) | Bacterial Strains and Fermentation Processes for the Production of 2-Keto-L-Gulonic Acid | |
AU2000246957A1 (en) | Bacterial Strains and Fermentation Processes for the Production of 2-Keto-L-Gulonic Acid | |
MXPA01002475A (en) | Bacterial strains for the production of 2-keto-l-gulonic acid | |
KR100297619B1 (en) | Method of manufacturing biotin | |
JP3176433B2 (en) | Method for producing zeaxanthin and a novel microorganism of the genus Flexibacter used therein | |
JP4505620B2 (en) | Microorganism producing icosapentaenoic acid and method for producing icosapentaenoic acid | |
JPH05328979A (en) | Production of zeaxanthin and novel flexibacter microorganism used therefor | |
JPH0378106B2 (en) | ||
MXPA99003710A (en) | Novel bacterial strains and use thereof in fermentation processes for 2-keto-l-gulonic acid production | |
JPH0549497A (en) | Method for producing zeaxanthin | |
Survase et al. | Biotehnološka proizvodnja vitamina | |
CZ289404B6 (en) | Strain of Nocardia sp. microorganism |